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Background: Calculation of individual risk is the cornerstone of effective cardiovascular prevention. arriba is a
software to estimate the individual risk to suffer a cardiovascular event in 10 years. Prognosis and the absolute
effects of pharmacological and lifestyle interventions help the patient make a well-informed decision. The risk
calculation algorithm currently used in arriba is based on the Framingham risk algorithm calibrated to the German
setting. The objective of this study is to evaluate and adapt the algorithm for the target population in primary care
in Germany.
Methods/design: arriba-pro will be conducted within the primary care scheme provided by a large health care
insurer in Baden-Württemberg, Germany. Patients who are counseled with arriba by their general practitioners (GPs)
will be included in the arriba-pro cohort. Exposure data from the consultation with arriba such as demographic
data and risk factors will be recorded automatically by the practice software and transferred to the study centre.
Information on relevant prescription drugs (effect modifiers) and cardiovascular events (outcomes) will be derived
from administrative sources.
Discussion: The study is unique in simulating a therapy naïve cohort, matching exactly research and application
setting, using a robust administrative data base, and, finally, including patients with known cardiovascular disease
who have been excluded from previous studies.
Trial registration: The study is registered with Deutsches Register Klinischer Studien (DRKS00004633).Background
Cardiovascular disease (CVD) is the leading cause of death
in industrialized and, increasingly, in developing countries
[1]. In 2008, 17.1 million deaths worldwide were caused
by cardiovascular disease, which amounts to 30% of all
deaths [2]. For Germany, the respective numbers are
342,000 cardiovascular deaths per year (40% of all deaths)
[3]. The prevention of cardiovascular diseases is thus an
area with high priority.
Within a high-risk prevention paradigm, persons with
elevated cardiovascular risk are identified and treated [4].
Here the focus has shifted from the diagnosis and treat-
ment of single risk factors to a view focusing on global
cardiovascular risk. On the basis of multivariate algo-
rithms clinicians can now calculate an individual’s* Correspondence: annette.diener@med.uni-rostock.de
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reproduction in any medium, provided the orcardiovascular risk. Behavioral and pharmacological inter-
ventions are offered only to high risk individuals. This ap-
proach maximizes absolute risk reduction and efficiency
compared to the treatment of individual risk factors [4-6].
The American Framingham study, starting 1948 and
still continuing, has been the first prospective study to
identify risk factors contributing to cardiovascular events
[7]. From this study the presumably best known and
most widely used risk algorithm was derived which was
subsequently validated for different populations [8,9].
Although these studies revealed that the Framingham al-
gorithm resulted in an overestimation of the actual ob-
served risk in populations different from the derivation
cohort (lack of calibration), its discrimination ability has
repeatedly been shown to be excellent [10].
The majority of consultations regarding cardiovascular
disease treatment and prevention takes place in primary
care [11]. Several tools, most of them based on the Fra-
mingham algorithm, are available to support practitionersLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Exposure variables
Demographics Age/year of birth
Gender
Insurance number
Cardiovascular risk factors Total Cholesterol mmol/L or mg/dL
HDL-Cholesterol mmol/L or mg/dL
Smoking yes/no
Systolic blood pressure mm Hg
Patient on blood pressure lowering
medication yes/no
Diabetes yes/no
Diabetes control glycosylated hemoglobin
Known atherosclerotic disease yes/no
Family history for cardiac disease yes/no
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arriba (www.arriba-hausarzt.de) has become the most
popular support tool. It has been developed by the
Departments of General Practice at Philipps University
Marburg and Rostock University. The arriba calculator is
based on the Framingham risk algorithm with calibration
for the German setting. This is achieved by a constant
multiplier derived from population cohorts [12]. 10-year
absolute risk for cardiovascular events is calculated based
on age, sex, blood pressure, lipids, smoking status, family
history and diabetes control [13]. For secondary preven-
tion, a simplified estimate is presented based on a preven-
tion trial cohort [14]. Individual risk as well as effects of
medication and behavioral change can easily be demon-
strated as absolute risk reduction. The software can be
freely downloaded by individual general practitioners
(GPs).
arriba has been designed to be used intuitively. Dem-
onstration of effects of single intervention and their
combinations does not require sophisticated understand-
ing of absolute and relative risk reduction. arriba thus
supports shared decision-making between physician and
patient as well as adherence to treatment plans [15,16].
arriba has been evaluated in a cluster randomized con-
trolled trial, in which patient satisfaction, participation,
and change in cardiovascular diseases risk status were
investigated. It could be shown that patients randomized
to the intervention group had a significant higher satis-
faction with process and result than controls [17]. The
acceptance by arriba among primary care physicians
varied, depending on their personal motivation, their at-
titude towards shared decision-making in general and
context variables such as time constraints [18].
Since 2004, primary care in Germany has increasingly
been provided within gatekeeping schemes (Hausarzt-
zentrierte Versorgung – HzV). In the German federal
state Baden-Württemberg arriba has been implemented
as part of the HzV of the Allgemeine Ortskrankenkasse
Baden-Württemberg (AOK BW), the largest statutory
non-profit health insurance in the federal state Baden-
Württemberg, Germany [19]. Regular automated data
transfer and consent by patients who participate in the
HzV has provided the opportunity to establish a cohort
to improve the arriba risk algorithm.
The study we are presenting here has as its objective the
validation and adaptation of the arriba risk algorithm for
future use in primary care. We will not only address pri-
mary prevention, but also prediction for patients with
known cardiovascular disease and/or diabetes mellitus.
Methods/design
arriba-pro is a prospective, longitudinal cohort study
based on medical and administrative data provided by pri-
mary care practices and a large health insurance company.Attending patients who enrolled in the HzV AOK BW
and are counseled with arriba by their GPs are eligible.
Participants and recruitment
In the Land of Baden-Württemberg (BW), about 1 mil-
lion members of the insurance company AOK BW are
voluntarily enrolled in the HzV AOK BW. 3,500 out of
7,100 GPs in BW have registered to provide primary
care services for these patients. For all GPs providing
HzV services specially designed software for documenta-
tion and billing is available, including the arriba soft-
ware. Every patient enrolled in the HzV-scheme for who
arriba is used can automatically be included into the
study after the approval of his/her GP.
Exposure, outcomes and effect modifiers
Exposure variables will include demographic data and
cardiovascular risk factors (see Table 1).
Acute coronary syndrome (fatal/non-fatal) and acute
stroke (fatal/non-fatal), excluding transient ischaemic at-
tacks, will be the main outcome of the study. Secondary
outcomes will be overall death, hospitalization for car-
diovascular disease, any hospitalization, revascularization
procedures (coronary and/or carotid vascular beds), and
outpatients’ cardiology consultations. The occurrence of
these will be determined from administrative data (see
below). Drug treatment prescribed after recruitment into
the study will be analyzed as potential confounder or ef-
fect modifier.
Data collection
During a consultation supported by arriba GPs will en-
ter the patient’s age, sex, cardiovascular risk factors and
the interventions that have been discussed with the pa-
tient. These data together with the calculated absolute
cardiovascular risk will automatically be stored within
the arriba software. GPs will always be asked for their
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red by the software and transferred for further proces-
sing. Data will be regularly transferred to the central
computing centre. From there the data will be sent to an
independent clinical trial centre (CTC North at University
Medical Center Hamburg Eppendorf). The CTC North
will provide data files to the collaborating departments at
the universities of Marburg and Rostock. These will in-
clude clinical data and pseudonymised identifiers for pa-
tients and GPs (see Figure 1).
Much care will be taken to preserve the confidentiality
of data from arriba counselling. Patients ID-numbers
will be pseudonymised with the key known only to AOK
BW. Clinical data will be encrypted so that only the par-
ticipating academic researchers will be able to read
them. At the CTC North GPs identifiers will also be
pseudonymised. The pseudonymisation procedure will
allow to link information of the same patient from dif-
ferent data sources while also maintaining full confiden-
tiality and privacy of patients’ and GPs’ data.Figure 1 Data-transmission and pseudonymisation steps.In order to obtain information on outcome and treat-
ments for participating patients, the AOK BW central
database will regularly be queried. The resulting data will
be provided to the academic departments at the univer-
sities of Marburg and Rostock via CTC North with all
the precautions regarding confidentiality described above.
These data will also include diagnostic codes, such as car-
diovascular events, and relevant vascular procedures, such
as percutaneous coronary interventions or coronary by-
pass surgery (see Figure 2).
Data analysis
The main purpose of the analysis is the validation and
adaptation of the risk algorithm presently implemented
in the arriba-software [20]. The current algorithm is
based on the Framingham cohort and is calibrated to
German populations. Exposure variables are limited to
the set currently recorded by the arriba-software (see
Table 1). As a result of our study we will be able to ad-
just their weights (coefficients) as well as the intercept
Figure 2 Data-matching and pseudonymisation steps.
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little and can thus be omitted, and specify interactions
between predictors.
We will use a stepwise procedure to analyze the data,
going from the mere descriptive analysis to the univariate-
and multivariate analysis, using the appropriate tools in
each step.
Among the predictors to be entered into the multivari-
ate model are time-independent variables, such as sex or
previous cardiovascular disease, but also time-dependent
factors, such as medication modifying cardiovascular risk.
For pragmatic reasons, cholesterol and blood pressure
levels will be regarded as time-independent since they
are either relatively stable characteristics (LDL-/HDL-
cholesterol) and/or cannot be measured over time
within the current study design (blood pressure, smok-
ing status). However, data on risk-modifying medication
(e.g. statins, blood-pressure lowering drugs) can be
retrieved from the AOK BW and be entered into the
model. Treatment is likely to change over time but this
can be accommodated in the statistical model.To adjust for the confounders mentioned above, an
extension of the Cox Proportional Hazards Model for
time-dependent variables will be used as suggested by
Kleinbaum [21]. To simulate a therapy naïve cohort, drug
treatments will be adjusted for. The statistical analysis will
be performed by the universities of Rostock und Marburg
with support of the Department of Medical Biometry and
Epidemiology, Hamburg.
Sample size
In the main analysis, we aim to validate and re-calibrate
the risk algorithm implemented in the arriba-software
for primary prevention. To quantify the impact of a pre-
dictor, at least 10 events are needed [22]. If we assume
patients in our cohort to have an average risk of a car-
diovascular event of 5% in 10 years, the study of 9 pre-
dictors (see Table 1) would require a sample of at least
1,800 patients. However, further analyses will require a
higher sample size. To validate the risk algorithm within
the subgroup of patients with a known coronary heart
disease a total sample size of 3,000 patients would be
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group is 10% of the total sample and that the average
risk of a cardiovascular event within this group is 30% in
10 years. Adjusting for the risk-modifying effect of treat-
ment will raise the number of covariates to be entered in
the models and the sample size accordingly. Within the
first two years, 466 GPs have recruited about 4,100 pa-
tients. Considering a total time of enrolment of 4 years,
the resulting sample size will meet our requirements
with a sufficient safety margin.
Ethics and funding
The study complies with the Declaration of Helsinki.
The research protocol was approved by the ethics com-
mittee at the University of Marburg (ID 159/11). All
patients who participate in the HzV AOK BW are asked
to give their written consent for personal data to be used
for research purposes.
A grant provided by the AOK allows a five years’ study
duration. However, funding for an extended study period
will be sought.
Discussion
The main aim of the cohort study outlined here is
the validation and adaptation of a cardiovascular risk
algorithm.
Cardiovascular risk algorithms have repeatedly been
shown to have limited predicting power when tested on
independent samples [10,23]. There are many reasons
for this unsatisfactory state, among these biological vari-
ability, demographic, social, and cultural differences be-
tween derivation and validation cohorts, comorbidities,
and intervention by health care providers outside the
study protocol, to name just a few.
Our study does address three of these in an innovative
way:
 Simulation of a therapy-naïve cohort: The main goal
of the arriba risk calculator is the unbiased
information of individual patients in primary care
practice. For individuals considering long-term
interventions such as lipid or blood-pressure
lowering therapy, predictive evidence should be
based on cohorts without interventions modifying
cardiovascular risk. However, this is unfeasible
since most subjects in the cohort will be treated
by their health care provider once a single risk
factor or their global cardiovascular risk is found
to be elevated. By accommodating drug therapy
during follow-up we will be able to simulate a
therapy-naïve cohort and thus provide risk
estimates not biased by pharmacological
interventions. To our knowledge this has not
been attempted before. Match between research and application setting:
Previously developed cardiovascular risk algorithms
were derived from geographically or occupationally
defined populations. This puts a limit on their
generalizability regarding counseling of individual
patients in primary care. Our study sample,
however, is drawn from exactly the population for
which the algorithm will be used once the study is
completed.
 Inclusion of patients with known cardiovascular
disease: Previously published risk algorithms were
derived from populations free of overt
cardiovascular disease. They can thus not be used to
inform decision-making for secondary prevention.
Against the background of aging populations with
high prevalence of cardiovascular disease, this is a
serious limitation. As a result of our study, a risk
calculator applicable to this group will be available.
The automatic arriba-data-collection of patients who
are enrolled in the GP centered health care contract
(HzV) is an elegant way to obtain relevant data. Patients
participating in the HzV tend to be slightly older and suf-
fer from a higher morbidity burden when compared with
those AOK insured, who are not enrolled in the HzV [24].
With the study design presented here we can describe the
characteristics of each individual of our cohort and so will
be able to adjust for possible confounders.
Selection bias may arise from selective use of arriba
by participating GPs. As a result, certain groups would
be underrepresented in our study sample because their
GPs are not interested in their arriba risk. This would
apply to patients at obviously very high or very low risk.
However, we are confident that, given our sample size,
these groups will still be sufficiently represented in our
study. Moreover, educational measures have been imple-
mented to encourage GPs using arriba in a broad range
of patients. If on the other hand GPs use the decision
tool arriba in a ‘selective’ way, then this is obviously the
population they feel to be in need of the information
provided by the software. As a result, a sample speci-
fically adapted to the needs of future users would be
assembled.
We will use administrative data of the AOK BW to as-
sess relevant medication as well as cardiovascular events.
These data can be expected to be highly valid since they
are based on claims by pharmacies, hospitals and physi-
cians [25]. An important data source will be the hospital
claims data set. In Germany a diagnosis related groups
(DRG) system is used for reimbursement of hospital ser-
vices. In the German DRG system, not only the main
diagnosis but also secondary diagnoses and main
procedures are coded and used to determine the
final DRG [26].
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status will only be evaluated at baseline, we will not be
able to take changes in smoking habits during follow-up
as well as other behavioral risk factors into account. The
set of risk factors (predictors) is limited to those cur-
rently included in the arriba risk calculator.
We are aware that in order to adapt and validate
a ten-year cardiovascular risk calculator an extended
follow-up period will be needed. Evidence based on
shorter follow-up periods will be only preliminary. We
therefore aim at longer follow-up than the five-year period
that we have obtained funding for so far.
Despite these limitations, the study presented here
provides an unusual opportunity to improve cardiovas-
cular risk prediction for primary care. Simulation of a
therapy naïve cohort, the exact match of research and
application setting, a robust administrative database, and,
finally, the inclusion of patients with known cardiovascu-
lar disease make this study unique in comparison with
previous adaptations of cardiovascular risk algorithms.
Competing interests
AA and NDB are chairmen of a non-profit company providing decision
support software to health care organisations and individual providers. The
arriba software is available free of charge from ‘www.arriba-hausarzt.de’. KK is
leader of the department prevention at the Federal Association of the AOK,
KT is project manager at the AOK Baden-Württemberg. The remaining
authors declare that they have no competing interests.
Authors’ contribution
AA and NDB conceived the study. All authors contributed to the planning of
the study. AD, SHC, and JH drafted the manuscript. All authors commented
on the draft and approved the final version of the manuscript.
Acknowledgements
The authors thank Ute Scholz and Thomas Scheithauer for their advice,
support, and commitment in the preparation of the study.
Funding
This study is funded by the AOK Bundesverband (German Federal
Association of Local Health Insurance Funds) and AOK Baden-Württemberg
(Baden-Württemberg Statutory Health Insurance Fund).
Author details
1Institute of General Practice, Rostock University Medical Center, 18055
Rostock , Germany. 2Department of General Practice/Family Medicine,
Medical Faculty, Philipps University Marburg, 35043 Marburg , Germany.
3Department of Medical Biometry and Epidemiology, University Medical
Center Hamburg-Eppendorf, 20246 Hamburg , Germany. 4Federal Association
of the AOK, 10178 Berlin , Germany. 5AOK Baden-Württemberg, 70191
Stuttgart , Germany.
Received: 21 December 2012 Accepted: 16 January 2013
Published: 22 January 2013
References
1. Bonow RO: World Heart Day 2002: The International Burden of
Cardiovascular Disease: Responding to the Emerging Global Epidemic.
Circulation 2002, 106:1602–5.
2. WHO: Cardiovascular Diseases (CVDs) Fact sheet No317; 2012. available from
http://www.who.int/mediacentre/factsheets/fs317/en/.
3. Destatis, Statistisches Bundesamt: Anzahl der Gestorbenen nach ausgewählten
Todesursachen 2011; 2012. available from https://www.destatis.de/DE/
ZahlenFakten/GesellschaftStaat/Gesundheit/Todesursachen/Tabellen/
EckdatenTU.html.4. Jackson R, Lawes CMM, Bennett DA, Milne RJ, Rodgers A: Treatment with
drugs to lower blood pressure and blood cholesterol based on an
individual’ s absolute cardiovascular risk. Lancet 2005, 365:434–41.
5. Smith SC, Jackson R, Pearson TA, Fuster V, Yusuf S, Faergeman O, Wood DA,
Alderman M, Horgan J, Home P, Hunn M, Grundy SM: Principles for
national and regional guidelines on cardiovascular disease prevention: a
scientific statement from the World Heart and Stroke Forum. Circulation
2004, 109:3112–21.
6. Eddy DM, Adler J, Patterson B, Lucas D, Smith KA, Morris M: Individualized
guidelines: the potential for increasing quality and reducing costs. Ann
Intern Med 2011, 154:627–34.
7. Anderson KM, Odell PM, Wilson PW, Kannel WB: Cardiovascular disease risk
profiles. Am Heart J 1991, 121:293–8.
8. Brindle P, Emberson J, Lampe F, Walker M, Whincup P, Fahey T, Ebrahim S:
Predictive accuracy of the Framingham coronary risk score in British
men: prospective cohort study. BMJ 2003, 327:1267–72.
9. Hense H: Framingham risk function overestimates risk of coronary heart
disease in men and women from Germany—results from the MONICA
Augsburg and the PROCAM cohorts. Eur Heart J 2003, 24:937–45.
10. Eichler K, Puhan MA, Steurer J, Bachmann LM: Prediction of first coronary
events with the Framingham score: a systematic review. Am Heart J 2007,
153:722–31. 731.e1–8.
11. Leal J, Luengo-Fernández R, Gray A, Petersen S, Rayner M: Economic
burden of cardiovascular diseases in the enlarged European Union.
Eur Heart J 2006, 27:1610–9.
12. MONICA. Monograph and multimedia sourcebook. World’s largest study of
heart disease, stroke, risk factors, and population trends, 1979–2002. Tunstall-
Pedoe H. (ed.) Geneva: World Health Organization; 2003.
13. Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Golden
SH: Meta-analysis: glycosylated hemoglobin and cardiovascular disease
in diabetes mellitus. Ann Intern Med 2004, 141:421–31.
14. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N,
Just H, Fox KA, Pocock SJ, Clayton TC, Motro M, Parker JD, Bourassa MG,
Dart AM, Hildebrandt P, Hjalmarson A, Kragten JA, Molhoek GP, Otterstad JE,
Seabra-Gomes R, Soler-Soler J, Weber S: Effect of long-acting nifedipine on
mortality and cardiovascular morbidity in patients with stable angina
requiring treatment (ACTION trial): randomised controlled trial. Lancet
2004, 364:849–57.
15. Wilson SR, Strub P, Buist AS, Knowles SB, Lavori PW, Lapidus J, Vollmer WM:
Shared treatment decision making improves adherence and outcomes
in poorly controlled asthma. Am J Respir Crit Care Med 2010, 181:566–77.
16. Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staak CP,
de Jong CA: Systematic review of the effects of shared decision-making
on patient satisfaction, treatment adherence and health status.
Psychother Psychosom 2008, 77:219–26.
17. Krones T, Keller H, Sadowski E, Baum E, Wegscheider K, Rochon J, Donner-
Banzhoff N: Absolute Cardiovascular Disease Risk and Shared Decision
Making in Primary Care: A Randomized Controlled Trial. Ann Fam Med
2008, 6:218–27.
18. Sadowski EM, Eimer C, Keller H, Krones T, Sönnichsen AC, Baum E, Donner-
Banzhoff N: Evaluation komplexer Interventionen: Implementierung von
ARRIBA-Herz, einer Beratungsstrategie für die Herz-Kreislaufprävention
[Evaluation of Complex Interventions: Implementation of ARRIBA-Herz, A
Counseling Strategy for Coronary Prevention]. Z Allgemeinmed 2005,
81:429–34.
19. Baden-Württemberg AOK: Geschäftsbericht 2011/2012 [Business Report 2011/
2012]; 2012. available from http://www.aok.de/assets/media/baden-
wuerttemberg/gb_2011_12_bawue_rz_ansicht_gesamt_11102012.pdf.
20. Toll DB, Janssen KJM, Vergouwe Y, Moons KGM: Validation, updating and
impact of clinical prediction rules: a review. J Clin Epidemiol 2008,
61:1085–94.
21. Kleinbaum DG, Klein M: Survival Analysis. 2nd edition. New York:
Springer-Verlag; 2005.
22. Harrell FE, Lee KL, Mark DB: Multivariable prognostic models: issues in
developing models, evaluating assumptions and adequacy, and
measuring and reducing errors. Stat Med 1996, 15:361–87.
23. Gorenoi V, Schönermark MP, Hagen A: Assessments tools for risk
prediction of cardiovascular diseases. GMS Health Technology Assessment
2009, 5. Doc11.
24. Freund T, Szecsenyi J, Ose D: Charakteristika von eingeschriebenen
Versicherten eines flächendeckenden Vertrages zur hausarztzentrierten
Diener et al. BMC Family Practice 2013, 14:13 Page 7 of 7
http://www.biomedcentral.com/1471-2296/14/13Versorgung [Characteristics of Beneficiaries of a GP-Centred Health Care
Contract in Germany]. Medizinische Klinik - Intensivmedizin und
Notfallmedizin 2010, 105:808–11.
25. van Walraven C, Austin P: Administrative database research has unique
characteristics that can risk biased results. J Clin Epidemiol 2012, 65:126–31.
26. Schreyogg J, Stargardt T: Gesundheitsökonomische Evaluation auf
Grundlage von GKV-Routinedaten [Health economic evaluation
based on administrative data from German health insurance].
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2012,
55:668–74.
doi:10.1186/1471-2296-14-13
Cite this article as: Diener et al.: In-vivo-validation of a cardiovascular
risk prediction tool: the arriba-pro study. BMC Family Practice 2013 14:13.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
